Kenvue Inc. (KVUE) - Dilution Analysis

10-Q filing | 1922.0M shares outstanding

10-Q filing | 1918.0M shares outstanding

10-Q filing | 1919.0M shares outstanding

10-Q filing | 1925.0M shares outstanding

10-K filing | 1915.0M shares outstanding

10-Q filing | 1915.0M shares outstanding

10-Q filing | 1915.0M shares outstanding

S-1 filing: S-1 filing for an offering of common stock by selling shareholders, who acquired the shares from Johnson & Johnson in exchange for outstanding indebtedness.

10-Q filing | 1915.0M shares outstanding

10-K filing | 1850.3M shares outstanding

10-Q filing | 1916.0M shares outstanding

10-Q filing | 1838.0M shares outstanding

10-Q filing | 1914.9M shares outstanding

8-K filing: Kenvue Inc. completed its initial public offering of 198,734,444 shares of common stock at $22.00 per share, resulting in net proceeds of $4,241 million and issued 1,716,159,990 shares of Kenvue Common Stock to Johnson & Johnson. ($4241.0M proceeds)

S-1/A filing: Registration of 151,204,000 shares of common stock with an additional 22,680,600 shares if the over-allotment option is exercised.

S-1/A filing: This S-1/A filing outlines an offering of common stock, with 151,204,000 shares offered initially and an additional 22,680,600 shares available through an underwriter option, with the net proceeds intended to partially compensate Johnson & Johnson for the transfer of the Consumer Health Business.

S-1/A filing: This S-1/A filing details an offering of common stock, with the underwriters having an option to purchase additional shares. The proceeds will primarily be used to pay Johnson & Johnson as consideration for the Consumer Health Business transfer, while retaining between $1.0 billion and $1.5 billion for general corporate purposes. Upon completion, Johnson & Johnson will own a significant percentage of the voting power.

S-1/A filing: S-1/A filing for an offering of common stock.

S-1/A filing: This S-1/A filing relates to an offering of common stock, with Johnson & Johnson retaining a significant percentage of voting power upon completion. The net proceeds from the offering and debt financing will be paid to Johnson & Johnson as partial consideration for the transfer of the Consumer Health Business. The company intends to list its shares on the NYSE under the symbol 'KVUE'.

S-1 filing: S-1 filing for an initial public offering of common stock. The company intends to list its shares on the NYSE under the symbol "KVUE". Johnson & Johnson will own a significant portion of the voting power upon completion of the offering.